全球首个!中国生物制药勇闯千亿赛道

药智网
21 Apr

近日,中国生物制药宣布其自主研发的潜在“First-in-class”镇痛新药TRD205正式启动临床2期研究。作为全球首个针对慢性术后神经痛并进入Ⅱ期临床阶段的1类创新药,该成果不仅标志着非阿片类镇痛药研发的重大突破,更有望重塑全球疼痛管理市场格局。机制创新TRD205的核心靶点是血管紧张素Ⅱ型2受体(AT2R)。研究发现,外周神经损伤后,AT2R被异常激活,通过诱导巨噬细胞释放活性氧/氮,引发...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10